Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

Effects of ciliary muscle plasmid electrotransfer of TNF-α soluble receptor variants in experimental uveitis.

Title :
Effects of ciliary muscle plasmid electrotransfer of TNF-α soluble receptor variants in experimental uveitis.
Authors :
Touchard, E.
Bloquel, C.
Bigey, P.
Kowalczuc, L.
Jonet, L.
Thillaye-Goldenberg, B.
Naud, M.-C.
Scherman, D.
de Kozak, Y.
BenEzra, D.
Behar-Cohen, F.
Show more
Subject Terms :
TUMOR necrosis factor
EYE inflammation
Source :
Gene Therapy; Jul2009, Vol. 16 Issue 7, p862-873, 12p, 1 Color Photograph, 2 Diagrams, 1 Chart, 4 Graphs
Academic Journal
Intraocular inflammation has been recognized as a major factor leading to blindness. Because tumor necrosis factor-α (TNF-α) enhances intraocular cytotoxic events, systemic anti-TNF therapies have been introduced in the treatment of severe intraocular inflammation, but frequent re-injections are needed and are associated with severe side effects. We have devised a local intraocular nonviral gene therapy to deliver effective and sustained anti-TNF therapy in inflamed eyes. In this study, we show that transfection of the ciliary muscle by plasmids encoding for three different variants of the p55 TNF-α soluble receptor, using electrotransfer, resulted in sustained intraocular secretion of the encoded proteins, without any detection in the serum. In the eye, even the shorter monomeric variant resulted in efficient neutralization of TNF-α in a rat experimental model of endotoxin-induced uveitis, as long as 3 months after transfection. A subsequent downregulation of interleukin (IL)-6 and iNOS and upregulation of IL-10 expression was observed together with a decreased rolling of inflammatory cells in anterior segment vessels and reduced infiltration within the ocular tissues. Our results indicate that using a nonviral gene therapy strategy, the local self-production of monomeric TNF-α soluble receptors induces a local immunomodulation enabling the control of intraocular inflammation.Gene Therapy (2009) 16, 862–873; doi:10.1038/gt.2009.43; published online 14 May 2009 [ABSTRACT FROM AUTHOR]
Copyright of Gene Therapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.